Mupirocin ointment with good spreadability and stability and preparation method thereof

Abstract

This invention discloses an easy-to-apply and highly stable mupirocin ointment and its preparation method, belonging to the field of pharmaceutical preparation technology. The invention first uses citric acid and glycerol to form an alcohol-soluble supramolecular system, then adds mupirocin to the supramolecular system to form a mixed solution; polyethylene glycol 3350, polyethylene glycol 400, and propylene glycol are mixed evenly to obtain a matrix solution; finally, the mixed solution and the matrix solution are mixed, stirred, and condensed to obtain the mupirocin ointment. The mupirocin ointment prepared by this invention is easy to apply and has good stability, showing broader application prospects.

Description

Technical Field

[0001] This invention relates to a mupirocin ointment that is easy to apply and has good stability, and its preparation method, belonging to the field of pharmaceutical preparation technology. Background Technology

[0002] Mupirocin is a broad-spectrum antibiotic primarily used to treat skin infections caused by Gram-positive cocci, such as impetigo, boils, and folliculitis. Its mechanism of action involves inhibiting isoleucine transferase, an enzyme involved in bacterial protein synthesis, thereby preventing bacterial growth and reproduction. Mupirocin ointment, as one of its main dosage forms, is favored by clinicians and patients due to its ease of use and good local absorption.

[0003] Although mupirocin ointment has significant efficacy in treating skin infections, existing mupirocin ointments still present some problems in practical use, which to some extent limit its widespread clinical application and convenience. These problems are as follows: (1) Uneven application Traditional mupirocin ointment typically has a viscous texture. This viscous texture requires considerable force to spread evenly on the skin, which is inconvenient for patients and can lead to uneven drug distribution, affecting treatment efficacy. This is especially true when treating large-area skin infections, where application is more difficult and medication waste is more likely. Furthermore, the viscous ointment may adhere to the skin surface during use, causing discomfort and potentially hindering daily activities.

[0004] (2) Poor stability Mupirocin ointment is susceptible to environmental factors during storage, such as temperature, humidity, and light, which can degrade the active ingredients and reduce its efficacy. For example, at high temperatures, the oil components in the ointment may oxidize, causing it to harden and accelerating the degradation of mupirocin, thus shortening its shelf life.

[0005] As people pay increasing attention to skin health, the performance requirements for topical medications are also rising. There is an urgent market need for a mupirocin ointment that is both easy to apply and has good stability to meet patients' needs for convenient and effective treatment. However, developing such an ointment is no easy task.

[0006] Currently, many researchers have improved the texture of ointments by adding different excipients, such as moisturizers and lubricants. However, these methods can only improve the application performance to a certain extent, and have limited impact on stability. Some researchers have also optimized the ointment preparation process, such as using different emulsifiers and controlling different reaction temperatures. However, these methods are complex to operate, costly, and difficult to promote on a large scale.

[0007] Therefore, there is an urgent need for a simple, low-cost method to prepare mupirocin ointment that is easy to apply and has good stability to meet market demand. Summary of the Invention

[0008] [Technical Issues] Mupirocin ointment is difficult to apply evenly, has poor stability, and some preparation methods are complex and costly.

[0009] [Technical Solution] To address the aforementioned problems, this invention provides an easy-to-apply and highly stable mupirocin ointment and its preparation method. Specifically, this invention first uses citric acid and glycerol to form an alcohol-soluble supramolecular system, then adds mupirocin to the supramolecular system to form a mixed solution; polyethylene glycol 3350, polyethylene glycol 400, and propylene glycol are mixed uniformly to obtain a matrix solution; finally, the mixed solution and the matrix solution are mixed, stirred, and condensed to obtain the mupirocin ointment. The mupirocin ointment prepared by this invention is easy to apply and has good stability, showing broader application prospects.

[0010] The first objective of this invention is to provide a method for preparing mupirocin ointment that is easy to apply and has good stability, comprising the following steps: (1) Citric acid and glycerol are mixed evenly at a molar ratio of 0.1-0.5:1 at 300-800 rpm and 70-80℃ to form a supramolecular system; then mupirocin is added to the supramolecular system and mixed evenly at 500-800 rpm and 70-80℃ to obtain a mixed system. (2) Dissolve and mix polyethylene glycol 3350, polyethylene glycol 400 and propylene glycol evenly to obtain a matrix solution; (3) Mix the mixed solution and the matrix solution, stir and condense to obtain mupirocin ointment.

[0011] In one embodiment of the present invention, the molar ratio of citric acid to glycerol in step (1) is 0.2-0.4:1, for example, the molar ratio of citric acid to glycerol is 0.2:1, 0.3:1, 0.4:1, and the specific values ​​between the above values ​​are not exhaustively listed in the present invention due to space limitations and for the sake of brevity.

[0012] In one embodiment of the present invention, the rotational speed at which the supramolecular system is formed in step (1) can be 300, 400, 500, 600, 700, 800 rpm, and specific values ​​between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0013] In one embodiment of the present invention, the temperature at which the supramolecular system is formed in step (1) can be 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80°C, and specific values ​​between the above-mentioned values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0014] In one embodiment of the present invention, the rotational speed at which the mixing system is formed in step (1) can be 500, 600, 700, 800 rpm, or specific values ​​between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0015] In one embodiment of the present invention, the temperature at which the mixed system is formed in step (1) can be 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80°C, and specific values ​​between the above-mentioned values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0016] In one embodiment of the present invention, the mass ratio of mupirocin to the supramolecular system in step (1) is 10-20:100; for example, the mass ratio of mupirocin to the supramolecular system is 10:100, 15:100, 20:100, and specific values ​​between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0017] In one embodiment of the present invention, the mass ratio of polyethylene glycol 3350, polyethylene glycol 400, and propylene glycol in step (2) is 50:30-50:1-5; for example, the mass ratio of polyethylene glycol 3350, polyethylene glycol 400, and propylene glycol is 50:30:1, 50:30:2, 50:30:3, 50:30:4, 50:30:5, 50:40:1, 50:40:2, 50:40:3, 50:40:4, 50:40:5, 50:50:1, 50:50:2, 50:50:3, 50:50:4, 50:50:5, and the specific values ​​between the above values ​​are not exhaustively listed in the present invention due to space limitations and for the sake of brevity.

[0018] In one embodiment of the present invention, the mass ratio of the mixed solution to the matrix solution in step (2) is 100-120:800-1100; for example, the mass ratio of the mixed solution to the matrix solution is 100:800, 100:900, 100:1000, 110:800, 110:900, 110:1000, 110:1100, 120:800, 120:800, 120:900, 120:1000, 120:1100, and specific values ​​between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0019] In one embodiment of the present invention, the dissolution in step (2) is carried out at 500-800 rpm and 80-90°C to achieve uniform mixing; for example, the dissolution speed can be 500, 600, 700, 800 rpm, and specific values ​​between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range; the dissolution temperature can be 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90°C, and specific values ​​between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0020] In one embodiment of the present invention, the stirring in step (3) is carried out at 50-100 rpm and 50-60°C for 30-60 min; for example, the stirring speed can be 50, 60, 70, 80, 90, 100 rpm, and specific values ​​between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range; the stirring temperature can be 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60°C, and specific values ​​between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range; the stirring time is 30, 35, 40, 45, 50, 55, 60 min, and specific values ​​between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0021] In one embodiment of the present invention, in step (3), condensation is to stop heating and continue stirring at 50-100 rpm until an ointment is formed; for example, the stirring speed can be 50, 60, 70, 80, 90, 100 rpm, and specific values ​​between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0022] The second objective of this invention is to prepare a mupirocin ointment that is easy to apply and has good stability using the method described in this invention.

[0023] A third objective of this invention is to provide a method for improving the uniformity and stability of mupirocin ointment application, comprising the following steps: (1) Citric acid and glycerol are mixed evenly at a molar ratio of 0.1-0.5:1 at 300-800 rpm and 70-80℃ to form a supramolecular system; then mupirocin is added to the supramolecular system and mixed evenly at 500-800 rpm and 70-80℃ to obtain a mixed system. (2) Dissolve and mix polyethylene glycol 3350, polyethylene glycol 400 and propylene glycol evenly to obtain a matrix solution; (3) Mix the mixed solution and the matrix solution, stir and condense to obtain mupirocin ointment.

[0024] In one embodiment of the present invention, the molar ratio of citric acid to glycerol in step (1) is 0.2-0.4:1, for example, the molar ratio of citric acid to glycerol is 0.2:1, 0.3:1, 0.4:1, and the specific values ​​between the above values ​​are not exhaustively listed in the present invention due to space limitations and for the sake of brevity.

[0025] In one embodiment of the present invention, the rotational speed at which the supramolecular system is formed in step (1) can be 300, 400, 500, 600, 700, 800 rpm, and specific values ​​between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0026] In one embodiment of the present invention, the temperature at which the supramolecular system is formed in step (1) can be 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80°C, and specific values ​​between the above-mentioned values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0027] In one embodiment of the present invention, the rotational speed at which the mixing system is formed in step (1) can be 500, 600, 700, 800 rpm, or specific values ​​between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0028] In one embodiment of the present invention, the temperature at which the mixed system is formed in step (1) can be 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80°C, and specific values ​​between the above-mentioned values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0029] In one embodiment of the present invention, the mass ratio of mupirocin to the supramolecular system in step (1) is 10-20:100; for example, the mass ratio of mupirocin to the supramolecular system is 10:100, 15:100, 20:100, and specific values ​​between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0030] In one embodiment of the present invention, the mass ratio of polyethylene glycol 3350, polyethylene glycol 400, and propylene glycol in step (2) is 50:30-50:1-5; for example, the mass ratio of polyethylene glycol 3350, polyethylene glycol 400, and propylene glycol is 50:30:1, 50:30:2, 50:30:3, 50:30:4, 50:30:5, 50:40:1, 50:40:2, 50:40:3, 50:40:4, 50:40:5, 50:50:1, 50:50:2, 50:50:3, 50:50:4, 50:50:5, and the specific values ​​between the above values ​​are not exhaustively listed in the present invention due to space limitations and for the sake of brevity.

[0031] In one embodiment of the present invention, the mass ratio of the mixed solution to the matrix solution in step (2) is 100-120:800-1100; for example, the mass ratio of the mixed solution to the matrix solution is 100:800, 100:900, 100:1000, 110:800, 110:900, 110:1000, 110:1100, 120:800, 120:800, 120:900, 120:1000, 120:1100, and specific values ​​between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0032] In one embodiment of the present invention, the dissolution in step (2) is carried out at 500-800 rpm and 80-90°C to achieve uniform mixing; for example, the dissolution speed can be 500, 600, 700, 800 rpm, and specific values ​​between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range; the dissolution temperature can be 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90°C, and specific values ​​between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0033] In one embodiment of the present invention, the stirring in step (3) is carried out at 50-100 rpm and 50-60°C for 30-60 min; for example, the stirring speed can be 50, 60, 70, 80, 90, 100 rpm, and specific values ​​between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range; the stirring temperature can be 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60°C, and specific values ​​between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range; the stirring time is 30, 35, 40, 45, 50, 55, 60 min, and specific values ​​between the above points. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0034] In one embodiment of the present invention, in step (3), condensation is to stop heating and continue stirring at 50-100 rpm until an ointment is formed; for example, the stirring speed can be 50, 60, 70, 80, 90, 100 rpm, and specific values ​​between the above values. Due to space limitations and for the sake of brevity, the present invention will not exhaustively list the specific values ​​included in the range.

[0035] [Beneficial Effects] (1) The mupirocin ointment prepared by the present invention has a high mupirocin content, and the content is >95% on the 20th day; that is, the content changes little on the 20th day at a high temperature of 40°C.

[0036] (2) The kinematic viscosity of the mupirocin ointment prepared by this invention is 37-38 mm. 2 The rotational viscosity is 4000-5000 mPa·s, which is suitable for application and provides good uniformity.

[0037] (3) The mupirocin ointment prepared by the present invention has a total impurity content of less than 0.25% after 6 months of storage, and has good stability.

[0038] (4) The mupirocin ointment prepared by the present invention is easy to spread evenly after centrifugation and has good centrifugal stability.

[0039] (5) The mupirocin ointment prepared by the present invention can ensure the effective concentration of mupirocin on the skin surface, thereby enhancing the inhibitory effect on bacteria and reducing possible side effects.

[0040] (6) The preparation method of the present invention is simpler and has lower cost. Detailed Implementation

[0041] The preferred embodiments of the present invention are described below. It should be understood that the embodiments are for better explanation of the present invention and are not intended to limit the present invention.

[0042] Test method: 1. Content testing: Mupirocin ointment was stored at 40°C for 0, 10, and 20 days; then, 15 mg samples were taken and the mupirocin content was tested by liquid chromatography.

[0043] 2. Viscosity test: Kinematic viscosity and rotational viscosity were determined according to the viscosity determination method in General Chapter 0633 of Part IV of the 2020 edition of the Chinese Pharmacopoeia.

[0044] 3. Storage stability test: Mupirocin ointment was placed at 45°C and 75% relative humidity for 6 months. Samples were taken at the end of the first, third, and sixth months of the test period to detect the content of related substances.

[0045] Specifically, chromatographic methods were used for testing. A phosphate buffer solution with a pH of 6.3 was used to prepare a sample solution with a mass fraction of 30% for the test sample. Mobile phase: Ammonium acetate solution at pH 5.7 Tetrahydrofuran; Column temperature: 30℃; Flow rate: 0.8 mL / min; Detection wavelength: 240nm; Injection volume: 20 μL; Elution: Ammonium acetate solution at pH 5.7 and 60% (v / v) aqueous ethanol solution.

[0046] 4. Centrifugal stability test: Mupirocin ointment was placed at 45℃ for 24 hours and centrifuged at 5000 rpm for 10 minutes to determine its application performance.

[0047] Mupirocin ointment was placed at 4°C for 24 hours and centrifuged at 5000 rpm for 10 minutes to determine its application properties.

[0048] Example 1 A method for preparing mupirocin ointment that is easy to apply and has good stability includes the following steps: (1) Citric acid and glycerol were mixed at a molar ratio of 0.3:1 at 700 rpm and 75°C to form a supramolecular system; then 15 mg mupirocin was added to 100 mg of the supramolecular system and mixed at 500 rpm and 70°C to obtain a mixed system. (2) Dissolve and mix 500mg polyethylene glycol 3350, 400mg polyethylene glycol 400 and 5mg propylene glycol at 600rpm and 85℃ to obtain a matrix solution; (3) Stir the mixed solution and the matrix solution at 90 rpm and 55°C for 60 min; stop heating and continue stirring at 100 rpm until an ointment is formed, thus obtaining mupirocin ointment.

[0049] Example 2 A method for preparing mupirocin ointment that is easy to apply and has good stability includes the following steps: (1) Citric acid and glycerol were mixed at a molar ratio of 0.4:1 at 700 rpm and 75°C to form a supramolecular system; then 20 mg mupirocin was added to 100 mg of the supramolecular system and mixed at 500 rpm and 70°C to obtain a mixed system. (2) Dissolve and mix 500 mg of polyethylene glycol 3350, 500 mg of polyethylene glycol 400 and 3 mg of propylene glycol at 600 rpm and 85 °C to obtain a matrix solution; (3) Stir the mixed solution and the matrix solution at 90 rpm and 55°C for 60 min; stop heating and continue stirring at 100 rpm until an ointment is formed, thus obtaining mupirocin ointment.

[0050] Example 3 A method for preparing mupirocin ointment that is easy to apply and has good stability includes the following steps: (1) Citric acid and glycerol were mixed at a molar ratio of 0.2:1 at 700 rpm and 75°C to form a supramolecular system; then 10 mg mupirocin was added to 100 mg of the supramolecular system and mixed at 500 rpm and 70°C to obtain a mixed system. (2) Dissolve and mix 500 mg of polyethylene glycol 3350, 300 mg of polyethylene glycol 400 and 3 mg of propylene glycol at 600 rpm and 85 °C to obtain a matrix solution; (3) Stir the mixed solution and the matrix solution at 90 rpm and 55°C for 60 min; stop heating and continue stirring at 100 rpm until an ointment is formed, thus obtaining mupirocin ointment.

[0051] Comparative Example 1 Compared to Example 1, the difference is that a supramolecular system is not used; the mixture is directly mixed. Specifically, the steps include the following: (1) Mix 38mg citric acid, 62mg glycerol and 5mg mupirocin at 700rpm and 75℃ to obtain a mixed system; (2) Dissolve and mix 500mg polyethylene glycol 3350, 400mg polyethylene glycol 400 and 5mg propylene glycol at 600rpm and 85℃ to obtain a matrix solution; (3) Stir the mixed solution and the matrix solution at 90 rpm and 55°C for 60 min; stop heating and continue stirring at 100 rpm until an ointment is formed, thus obtaining mupirocin ointment.

[0052] Comparative Example 2 Compared to Example 1, the difference is that the preparation is done by direct mixing in a one-pot method: Specifically, the steps include the following: 38 mg citric acid, 62 mg glycerin, 5 mg mupirocin, 500 mg polyethylene glycol 3350, 400 mg polyethylene glycol 400, and 5 mg propylene glycol were stirred at 900 rpm and 85°C for 120 min. Heating was stopped, and stirring was continued at 100 rpm until an ointment was formed, thus obtaining mupirocin ointment.

[0053] Comparative Example 3 Compared with Example 1, the difference is that citric acid is replaced with malic acid; Specifically, the steps include the following: (1) Malic acid and glycerol were mixed at a molar ratio of 0.3:1 at 700 rpm and 75°C to form a supramolecular system; then 15 mg mupirocin was added to 100 mg of the supramolecular system and mixed at 500 rpm and 70°C to obtain a mixed system. (2) Dissolve and mix 500mg polyethylene glycol 3350, 400mg polyethylene glycol 400 and 5mg propylene glycol at 600rpm and 85℃ to obtain a matrix solution; (3) Stir the mixed solution and the matrix solution at 90 rpm and 55°C for 60 min; stop heating and continue stirring at 100 rpm until an ointment is formed, thus obtaining mupirocin ointment.

[0054] Comparative Example 4 Compared with Example 1, the difference is that glycerol is replaced with propylene glycol; Specifically, the steps include the following: (1) Citric acid and propylene glycol were mixed at a molar ratio of 0.3:1 at 700 rpm and 75°C to form a supramolecular system; then 15 mg mupirocin was added to 100 mg of the supramolecular system and mixed at 500 rpm and 70°C to obtain a mixed system. (2) Dissolve and mix 500mg polyethylene glycol 3350, 400mg polyethylene glycol 400 and 5mg propylene glycol at 600rpm and 85℃ to obtain a matrix solution; (3) Stir the mixed solution and the matrix solution at 90 rpm and 55°C for 60 min; stop heating and continue stirring at 100 rpm until an ointment is formed, thus obtaining mupirocin ointment.

[0055] The obtained mupirocin ointment was subjected to performance testing, and the test results are as follows: As shown in Table 1, the mupirocin ointments prepared in Examples 1-3 have a high mupirocin content, exceeding 95% on day 20; that is, the content change is small over 20 days at a high temperature of 40°C. In contrast, the mupirocin ointments prepared in Comparative Examples 1-4 have a mupirocin content less than 90% on day 20, exhibiting significant content variation and poor stability.

[0056] Table 1

[0057] As can be seen from Table 2, the kinematic viscosity of the mupirocin ointment prepared in Examples 1-3 is 37-38 mm. 2 The rotational viscosity is 4000-5000 mPa·s, which is suitable for application; the kinematic viscosity of the mupirocin ointment prepared in Comparative Examples 1 and 2 is 38-41 mm / s. 2 The rotational viscosity is 5000-5500 mPa·s, making it difficult to apply; the kinematic viscosity of the mupirocin ointment prepared in Comparative Examples 3 and 4 is 35-38 mm / s. 2 The rotational viscosity is 3500-4000 mPa·s, which is relatively low, making it difficult to completely cover the skin surface and exert its effect. In other words, if the ointment viscosity is too low, the solution is too thin, making it easy to apply but difficult to evenly cover the skin surface; if the viscosity is too high, it may result in uneven application due to its excessive viscosity.

[0058] Table 2

[0059] As shown in Table 3, the mupirocin ointment prepared in Examples 1-3 had a total impurity content of less than 0.25% after 6 months of storage, indicating good stability. In contrast, the mupirocin ointment prepared in Comparative Examples 1-4 had a content of more than 0.30% after 6 months of storage, indicating poor stability.

[0060] Table 3. Results of Total Impurities Test in Ointment

[0061] As can be seen from Table 4, the mupirocin ointment prepared in Examples 1-3 is easy to spread evenly after centrifugation; that is, it has good centrifugal stability.

[0062] Table 4 Centrifugation stability test results

[0063] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.

Claims

1. A method for preparing mupirocin ointment that is easy to apply and has good stability, characterized in that, Includes the following steps: (1) Citric acid and glycerol are mixed at a molar ratio of 0.2-0.4:1 at 300-800 rpm and 70-80℃ to form a supramolecular system; then mupirocin is added to the supramolecular system and mixed at 500-800 rpm and 70-80℃ to obtain a mixed solution. The mass ratio of mupirocin to the supramolecular system is 10-20:

100. (2) Dissolve and mix polyethylene glycol 3350, polyethylene glycol 400 and propylene glycol evenly to obtain a matrix solution; wherein the mass ratio of polyethylene glycol 3350, polyethylene glycol 400 and propylene glycol is 50:30-50:1-5; (3) Mix the mixed solution and the matrix solution, stir, and condense to obtain mupirocin ointment; The mass ratio of the mixed solution to the matrix solution is 100-120:800-1100.

2. The method according to claim 1, characterized in that, In step (2), the dissolution is carried out at 500-800 rpm and 80-90℃ to dissolve and mix evenly.

3. The method according to claim 1, characterized in that, In step (3), the stirring is carried out at 50-100 rpm and 50-60℃ for 30-60 minutes.

4. The mupirocin ointment prepared by the method according to any one of claims 1-3 is easy to apply and has good stability.

Images